Advertisement

Epidemiological, Clinical and Outcome Aspects of Patients with Cryptococcosis Caused by Cryptococcus gattii from a Non-endemic Area of Brazil

  • Alessandro Henrique Damasceno-Escoura
  • Matheus Lucas de Souza
  • Felipe de Oliveira Nunes
  • Thiago César Pardi
  • Fernanda Castro Gazotto
  • Danilo Heitor Florentino
  • Delio José Mora
  • Mario León Silva-Vergara
Original Paper
  • 34 Downloads

Abstract

Cryptococcosis by Cryptococcus gattii occurs mainly in immunocompetent hosts, however, during the last decades, a growing number of cases in immunocompromised individuals have been noticed around the world. This report presents epidemiological, clinical and outcome aspects of patients with cryptococcosis caused by this species from a non-endemic area in Brazil. Of 278 Cryptococcus spp. clinical isolates recovered during the same period, 267 (96%) were molecularly identified as Cryptococcus neoformans VNI genotype and 11 (4%) as C. gattii VGII genotype by URA-5 RFLP. Of the 11 C. gattii patients, eight were male, mean age of 47.5 years. Of these, four were HIV-infected, one was kidney transplanted, one presented low CD4+ T cells values of unknown cause, another presented chronic liver disease meanwhile the remaining four were apparently immunocompetent. Disseminated disease and cryptococcal meningitis were present in four patients each. Most patients received amphotericin B plus fluconazole. Seven out of the 11 patients cured and four died before or during the therapy. The increased number of individuals with cryptococcosis by this species during the last decades needs to be carefully evaluated specially those who are HIV-infected. Nevertheless, Cryptococcus species differentiation is currently relevant in order to better know their relation with geographical, clinical host preference and outcome particularities.

Keywords

Cryptococcosis Cryptococcus gattii URA5-RFLP HIV infection VGII genotype Cryptococcal meningitis AIDS Immunocompetent host 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest. The authors alone are responsible for the content and the writing of the paper.

References

  1. 1.
    Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525–30.  https://doi.org/10.1097/QAD.0b013e328322ffac.CrossRefPubMedGoogle Scholar
  2. 2.
    Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–81.  https://doi.org/10.1016/S1473-3099(17)30243-8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kiertiburanakul S, Wirojtananugoon S, Pracharktam R, Sungkanuparph S. Cryptococcosis in human immunodeficiency virus-negative patients. Int J Infect Dis. 2006;10(1):72–8.CrossRefGoogle Scholar
  4. 4.
    Kidd SE, Chow Y, Mak S, et al. Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States. Appl Environ Microbiol. 2007;73(5):1433–43.CrossRefGoogle Scholar
  5. 5.
    MacDougall L, Kidd SE, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis. 2007;13(1):42–50.CrossRefGoogle Scholar
  6. 6.
    MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg Infect Dis. 2011;17(2):193–9.  https://doi.org/10.3201/eid1702.101020.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bartlett KH, Cheng PY, Duncan C, et al. A decade of experience: Cryptococcus gattii in British Columbia. Mycopathologia. 2012;173(5–6):311–9.  https://doi.org/10.1007/s11046-011-9475-x.CrossRefPubMedGoogle Scholar
  8. 8.
    Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J Infect Dis. 2005;192(5):888–92.CrossRefGoogle Scholar
  9. 9.
    Steele KT, Thakur R, Nthobatsang R, Steenhoff AP, Bisson GP. In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Med Mycol. 2010;48(8):1112–5.  https://doi.org/10.3109/13693781003774689.CrossRefPubMedGoogle Scholar
  10. 10.
    Galanis E, Macdougall L, Kidd S, Morshed M, British Columbia Cryptococcus gattii Working Group. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007. Emerg Infect Dis. 2010;16(2):251–7.  https://doi.org/10.3201/eid1602.090900.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis. 1995;20(3):611–6.CrossRefGoogle Scholar
  12. 12.
    Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 1995;21(1):28–34.CrossRefGoogle Scholar
  13. 13.
    Pappas PG. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc. 2013;124:61–79.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis. 2000;31(2):499–508.CrossRefGoogle Scholar
  15. 15.
    Chau TT, Mai NH, Phu NH, et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam: high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis. 2010;10:199.  https://doi.org/10.1186/1471-2334-10-199.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nakao M, Muramatsu H, Takahashi T, et al. Cryptococcus gattii genotype VGIIa infection in an immunocompetent Japanese patient: a case report and mini-review. Intern Med. 2016;55(20):3021–4.CrossRefGoogle Scholar
  17. 17.
    Byrnes EJ III, Li W, Lewit YP, et al. First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS ONE. 2009;4(6):e5851.CrossRefGoogle Scholar
  18. 18.
    Morgan J, McCarthy KM, Gould S, et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002–2004. Clin Infect Dis. 2006;43(8):1077–80.CrossRefGoogle Scholar
  19. 19.
    Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982;15(3):535–7.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. IberoAmerican Cryptococcal Study Group. Emerg Infect Dis. 2003;9(2):189–95.CrossRefGoogle Scholar
  21. 21.
    Galanis E, Hoang L, Kibsey P, et al. Clinical presentation, diagnosis and management of Cryptococcus gattii cases: lessons learned from British Columbia. Can J Dis Med Microbiol. 2009;20:23–8.CrossRefGoogle Scholar
  22. 22.
    Byrnes EJ 3rd, Marr KA. The outbreak of Cryptococcus gattii in Western North America: epidemiology and clinical issues. Curr Infect Dis Rep. 2011;13(3):256–61.  https://doi.org/10.1007/s11908-011-0181-0.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis. 2012;53(12):1188–95.CrossRefGoogle Scholar
  24. 24.
    Byrnes EJ 3rd, Bartlett KH, Perfect JR, Heitman J. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect. 2011;13(11):895–907.  https://doi.org/10.1016/j.micinf.2011.05.009.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chaturvedi V, Chaturvedi S. Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol. 2011;19(11):564–71.CrossRefGoogle Scholar
  26. 26.
    Springer DJ, Billmyre RB, Filler EE, et al. Cryptococcus gattii VGIII isolates causing infections in HIV/AIDS patients in Southern California: identification of the local environmental source as arboreal. PLoS Pathog. 2014;10(8):e1004285.  https://doi.org/10.1371/journal.ppat.1004285.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Datta K, Bartlett KH, Baer R, et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis. 2009;15(8):1185–91.CrossRefGoogle Scholar
  28. 28.
    Chowdhary A, Randhawa HS, Boekhout T, et al. Temperate climate niche for Cryptococcus gattii in Northern Europe. Emerg Infect Dis. 2012;18(1):172–4.  https://doi.org/10.3201/eid1801.111190.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA. 2004;101(49):17258–63.CrossRefGoogle Scholar
  30. 30.
    Trilles L, Lazéra Mdos S, Wanke B, et al. Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz. 2008;103(5):455–62.CrossRefGoogle Scholar
  31. 31.
    Brito-Santos F, Barbosa GG, Trilles L, et al. Environmental isolation of Cryptococcus gattii VGII from indoor dust from typical wooden houses in the deep Amazonas of the Rio Negro basin. PLoS ONE. 2015;10(2):e0115866.  https://doi.org/10.1371/journal.pone.0115866.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Freire AK, dos Santos Bentes A, de Lima Sampaio I, et al. Molecular characterization of the causative agents of Cryptococcosis in patients of a tertiary healthcare facility in the state of Amazonas-Brazil. Mycoses. 2012;55(3):e145–50.CrossRefGoogle Scholar
  33. 33.
    Santos WR, Meyer W, Wanke B, et al. Primary endemic Cryptococcosis gattii by molecular type VGII in the state of Pará, Brazil. Mem Inst Oswaldo Cruz. 2008;103(8):813–8.CrossRefGoogle Scholar
  34. 34.
    Martins LM, Wanke B, Lazéra Mdos S, et al. Genotypes of Cryptococcus neoformans and Cryptococcus gattii as agents of endemic cryptococcosis in Teresina, Piauí (northeastern Brazil). Mem Inst Oswaldo Cruz. 2011;106(6):725–30.CrossRefGoogle Scholar
  35. 35.
    Hagen F, Ceresini PC, Polacheck I, et al. Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest. PLoS ONE. 2013;8(8):e71148.  https://doi.org/10.1371/journal.pone.0071148.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Souto AC, Bonfietti LX, Ferreira-Paim K, et al. Population genetic analysis reveals a high genetic diversity in the Brazilian Cryptococcus gattii VGII population and shifts the global origin from the Amazon rainforest to the semi-arid desert in the Northeast of Brazil. PLoS Negl Trop Dis. 2016;10(8):e0004885.  https://doi.org/10.1371/journal.pntd.0004885.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ngamskulrungroj P, Gilgado F, Faganello J, et al. Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. PLoS ONE. 2009;4(6):e5862.  https://doi.org/10.1371/journal.pone.0005862.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Meyer W, Aanensen DM, Boekhout T, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol. 2009;47(6):561–70.  https://doi.org/10.1080/13693780902953886.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Severo LC, de Mattos Oliveira F, Londero AT. Cryptococcosis due to Cryptococcus neoformans var. gattii in Brazilian patients with AIDS. Report of three cases. Rev Iberoam Micol. 1999;16(3):152–4.PubMedGoogle Scholar
  40. 40.
    Fernandes Ode F, Costa TR, Costa MR, Soares AJ, Pereira AJ, Silva Mdo R. Cryptococcus neoformans isolated from patients with AIDS. Rev Soc Bras Med Trop. 2000;33(1):75–8.CrossRefGoogle Scholar
  41. 41.
    Chayakulkeeree M, Wangchinda P. Clinical characteristics and outcomes of patients with cryptococcal meningoencephalitis in a resource-limited setting. J Med Assoc Thai. 2014;97(Suppl 3):S26–34.PubMedGoogle Scholar
  42. 42.
    Chen SC, Slavin MA, Heath CH, et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis. 2012;55(6):789–98.CrossRefGoogle Scholar
  43. 43.
    Ecevit IZ, Clancy CJ, Schmalfuss IM, Nguyen MH. The poor prognosis of central nervous system cryptococcosis among nonimmunosuppressed patients: a call for better disease recognition and evaluation of adjuncts to antifungal therapy. Clin Infect Dis. 2006;42(10):1443–7.CrossRefGoogle Scholar
  44. 44.
    Leão CA, Ferreira-Paim K, Andrade-Silva L, et al. Primary cutaneous cryptococcosis caused by Cryptococcus gattii in an immunocompetent host. Med Mycol. 2011;49(4):352–5.  https://doi.org/10.3109/13693786.2010.530697.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Alessandro Henrique Damasceno-Escoura
    • 1
  • Matheus Lucas de Souza
    • 1
  • Felipe de Oliveira Nunes
    • 1
  • Thiago César Pardi
    • 1
  • Fernanda Castro Gazotto
    • 1
  • Danilo Heitor Florentino
    • 1
  • Delio José Mora
    • 1
  • Mario León Silva-Vergara
    • 1
  1. 1.Internal Medicine Department, Infectious Diseases UnitTriângulo Mineiro Federal UniversityUberabaBrazil

Personalised recommendations